Hunan Kelun Pharmaceutical Co., Ltd.

Main purpose: This study aims to study the pharmacokinetic characteristics of a single fasting intravenous drip of sodium butylphthalide injection (100 ml: 25 mg butylphthalide and 0.9 g sodium chloride) developed and produced by Jiangxi Kelun Pharmaceutical Co., Ltd. in healthy subjects; using sodium butylphthalide injection (ENBIP®, 100 ml: 25 mg butylphthalide and 0.9 g sodium chloride) produced by CSPC Pharmaceutical Group Enbi Pharmaceutical Co., Ltd. as the reference preparation, compare the pharmacokinetic parameters of the two preparations and evaluate the human bioequivalence of the two preparations. Secondary purpose: To evaluate the safety of the test preparation and the reference preparation in healthy subjects.

Primary objective: Using pharmacokinetic parameters as the primary endpoint evaluation indicators, the pharmacokinetic behavior of the test preparation Perampanel Oral Suspension (licensed by Hunan Kelun Pharmaceutical Co., Ltd.) and the reference preparation Perampanel Oral Suspension (licensed by Eisai Europe Limited, trade name: Fycompa®) in healthy subjects after oral administration in the fasting/postprandial state was compared to evaluate the bioequivalence of the two preparations. Secondary objective: To observe the safety of the test preparation Perampanel Oral Suspension and the reference preparation Perampanel Oral Suspension in healthy subjects. To evaluate the palatability of the test preparation Perampanel Oral Suspension and the reference preparation Perampanel Oral Suspension.

The main purpose of the study is to evaluate the pharmacokinetic characteristics of the test preparation of pilocarpine hydrochloride eye drops and the reference preparation of pilocarpine hydrochloride eye drops (Vuity). The secondary purpose of the study is to investigate the safety of the test preparation and the reference preparation after administration to the subjects.